BioSpace

Analysts at Guggenheim Partners expect Voyxact to see “broad commercial uptake” given its relatively broad label compared with previous accelerated approvals for IgA nephropathy. #approvals #FDA #biospace https://hubs.li/Q03VXFNd0

The discounts should be compared against the drugs’ “ultimate net price” rather than their indicated list price to gauge the true impact of the negotiations, BMO Capital Markets analysts said. #glp1 #drugpricing #biopharma #biospace https://hubs.li/Q03VXBhx0

Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers. #pharma #biospace https://hubs.li/Q03VXFkZ0

A coordinated national effort is emerging to bring alternatives to animal testing into routine preclinical use, backed by a fresh FDA roadmap and a global coalition of scientific and industry partners.  #FDA #biopharma #biospace https://hubs.li/Q03VXFNT0

The record-setting government shutdown was just the latest blow to the U.S. biopharma industry. When science funding becomes a casualty of political gridlock, we lose valuable talent, erode public trust and jeopardize our position as a global leader in innovation. #opinion #biopharma #biospace https://hubs.li/Q03VXDzc0

For those with the holidays on their minds this week and in the coming weeks, we’re curious what’s on your wish list for the biopharma industry. Please take a moment to share your thoughts in our brief survey. If we use your response in our story, you’ll remain anonymous unless you request we use your name. https://lnkd.in/gQjKqcuP

The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access to patients two years and older in what one Stanford Medicine professor called a “game changing advance” for the field. #FDA #genetherapy #pharma #biospace https://hubs.li/Q03VQytG0

At one point in merger negotiations with Novartis, Avidity CEO Sarah Boyce and her team walked, cutting off access to a data room and moving on to a capital raise. #pharma #biospace https://hubs.li/Q03VQyzb0

Novo Nordisk's amycretin showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes, suggesting its efficacy could become even stronger with longer follow-up, according to analysts at BMO Capital Markets. #obesity #weightloss #diabetes #biospace https://hubs.li/Q03VPJP_0

Novartis will cut 550 full-time jobs by the end of 2027 at a facility in its home country of Switzerland. The cuts come as the pharma is ending production of tablets and capsules and sterile medicines packaging at a plant in Stein, Switzerland. #layoffs #pharma #biospace https://hubs.li/Q03VQyB_0